Literature DB >> 33231712

Synergistic effect of PAF inhibition and X-ray irradiation in non-small cell lung cancer cells.

Yamei Chen1, Ying Jin1,2, Hangjie Ying1, Peng Zhang1, Ming Chen3,4, Xiao Hu5,6.   

Abstract

PURPOSE: Proliferating cell nuclear antigen-associated factor (PAF) is involved in cancer cell growth and associated with cell death induced by ultraviolet (UV) radiation. However, the contribution of PAF to radiotherapy sensitivity in non-small cell lung cancer (NSCLC) is unknown. The aim of this study was to investigate the relationship between PAF expression and radiotherapy response in NSCLC.
METHODS: Associations between PAF expression and patient survival outcomes were evaluated using publicly available online gene expression datasets. RNA interference was performed to knockdown PAF expression in the NSCLC cells. The effects of PAF knockdown on cell proliferation, migration, apoptosis, DNA damage, and activation of MEK/ERK and Wnt/β-catenin signaling pathways following X‑ray irradiation were evaluated in vitro.
RESULTS: PAF was found to be overexpressed in lung cancer tissues compared with normal samples, and elevated PAF expression was significantly correlated with inferior patient survival. In vitro, knockdown of PAF inhibited cell proliferation, cell apoptosis, and migration induced by X‑ray irradiation. Moreover, X‑ray-induced intracellular DNA strand damage was more obvious following PAF knockdown. Additionally, PAF knockdown inhibited activation of the MEK/ERK and Wnt/β-catenin signaling pathways in X‑ray-irradiated A549 cells.
CONCLUSION: These data demonstrate that reduced expression of PAF enhances radiosensitivity in NSCLC cells. Mechanistically, inhibition of the MEK/ERK and Wnt/β-catenin signaling pathways caused by PAF interference may lead to impaired cell function and enhance sensitivity to X‑rays. Targeting PAF may therefore serve as a potential therapeutic strategy to increase the efficiency of radiotherapy in NSCLC patients, ultimately improving patient survival.

Entities:  

Keywords:  KIAA0101; Lung adenocarcinoma; Lung cancer; Proliferating cell nuclear antigen-associated factor; Radiosensitivity

Mesh:

Substances:

Year:  2020        PMID: 33231712     DOI: 10.1007/s00066-020-01708-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  4 in total

1.  LncRNA PART1 promotes cell proliferation and progression in non-small-cell lung cancer cells via sponging miR-17-5p.

Authors:  Yeye Chen; Xiaoyun Zhou; Cheng Huang; Li Li; Yingzhi Qin; Zhenhuan Tian; Jia He; Hongsheng Liu
Journal:  J Cell Biochem       Date:  2020-12-27       Impact factor: 4.429

2.  [Primary gamma-induced unrepairable DNA damage in HeLa cells].

Authors:  V A Struchkov; N I Demidova; N B Strazhevskaia
Journal:  Biull Eksp Biol Med       Date:  1997-07

3.  Prevention of γ-Radiation-Induced DNA Damage in Human Lymphocytes Using a Serine-Magnesium Sulfate Mixture.

Authors:  Vahid Changizi; Mona Bahrami; Mahbod Esfahani; Seyed V Shetab-Boushehri
Journal:  Sultan Qaboos Univ Med J       Date:  2017-06-20

4.  Cordycepin promotes apoptosis by modulating the ERK-JNK signaling pathway via DUSP5 in renal cancer cells.

Authors:  Jung-Hoo Hwang; Jong Cheon Joo; Dae Joon Kim; Eunbi Jo; Hwa-Seung Yoo; Kyung-Bok Lee; Soo Jung Park; Ik-Soon Jang
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

  4 in total
  3 in total

1.  Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer.

Authors:  Qing Ma; Kai Geng; Ping Xiao; Lili Zeng
Journal:  Biomed Res Int       Date:  2021-09-02       Impact factor: 3.411

2.  Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation.

Authors:  Tina Jost; Lucie Heinzerling; Rainer Fietkau; Markus Hecht; Luitpold V Distel
Journal:  Front Oncol       Date:  2021-10-13       Impact factor: 6.244

3.  Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients.

Authors:  Tina Jost; Barbara Schuster; Lucie Heinzerling; Thomas Weissmann; Rainer Fietkau; Luitpold V Distel; Markus Hecht
Journal:  Strahlenther Onkol       Date:  2022-04-26       Impact factor: 4.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.